India to Malaysia: Arishta Export Trade Route

To import finished pharmaceutical formulations containing Arishta into Malaysia, the following steps must be undertaken:

1. Product Registration: All pharmaceutical products intended for importation, manufacture, distribution, or sale in Malaysia must be registered with the NPRA to ensure their safety, efficacy, and quality.

2. Dossier Submission: The registration dossier should follow the ASEAN Common Technical Dossier (ACTD) format, encompassing administrative, quality, non-clinical, and clinical documentation.

3. Marketing Authorization Holder (MAH): Only a company that is locally registered with the Drug Control Authority (DCA) and holds a valid Manufacturer’s License or Import License can act as the MAH.

4. Evaluation Timeline: The evaluation of prescription drugs, non-prescription drugs, new drugs, and biologicals typically lasts between 210 to 245 working days.

5. Registration Fees: For pharmaceutical product registration, the processing fee is RM 1,000. The fee for a single active ingredient is RM 1,200, whereas for two or more active ingredients, the fee is RM 2,000.

6. GMP Inspection: The NPRA requires evidence that the manufacturing premises conform to current Good Manufacturing Practice (GMP) requirements. This may involve submitting acceptable GMP evidence or undergoing a GMP inspection. (npra.gov.my)

Indian manufacturers exporting Arishta formulations to Malaysia must comply with the following GMP standards:

1. GMP Certification: Manufacturers must provide acceptable evidence demonstrating adherence to internationally accepted GMP standards recognized by the NPRA. (npra.gov.my)

2. GMP Inspection: The NPRA may conduct inspections to assess compliance with GMP requirements. The current PIC/S Guide to GMP for Medicinal Products and its Annexes are adopted as the standard used by NPRA for this purpose. (npra.gov.my)

3. Approved Facilities: Manufacturers should ensure their facilities are listed under the ASEAN Sectoral Mutual Recognition Arrangement (MRA) on GMP Inspection of Manufacturers of Medicinal Products, if applicable. (npra.gov.my)

4. Regulatory Actions: Manufacturers must stay informed about any regulatory actions or inspections conducted by the NPRA to ensure ongoing compliance.

Several regulatory changes have occurred in Malaysia between 2024 and 2026 that may impact the importation of Arishta formulations:

1. Drug Registration Guidance Document (DRGD) Update: In January 2026, the NPRA released the 11th revision of the DRGD, providing updated guidelines for the registration process, including quality control, inspection, licensing, and post-registration activities. (npra.gov.my)

2. Animal-Derived Ingredients Labeling: Effective August 1, 2024, the NPRA mandated the declaration of animal-sourced ingredients on product labels for pharmaceuticals, traditional medicines, and health supplements. This includes active ingredients, excipients, and starting materials like gelatin.

3. GMP Inspection Framework: In March 2021, the NPRA published the 7th edition of the Foreign GMP Inspection Guidance Document, outlining the requirements for foreign manufacturers to demonstrate GMP compliance. (npra.gov.my)

Staying abreast of these developments is crucial for ensuring compliance with Malaysia's regulatory requirements for importing pharmaceutical products.

TARIFF_NOTES: Pharmaceutical products classified under HS code 30049011 are exempt from import duties in Malaysia.

Arishta formulations, traditional Ayurvedic medicinal products, have a niche presence in Malaysia's pharmaceutical market. The demand for such herbal formulations is influenced by factors including the prevalence of lifestyle-related ailments, increasing health consciousness, and a growing preference for natural remedies. In 2024, Malaysia's total pharmaceutical imports amounted to approximately $2.5 billion, with herbal and traditional medicines constituting around 10% of this figure. Domestic production of herbal medicines is limited, leading to a reliance on imports to meet consumer demand.

Malaysia imposes a 0% import duty on pharmaceutical products under HS code 30049011, which includes finished formulations containing Arishta. Additionally, these products are subject to a 6% Goods and Services Tax (GST). The Malaysia-India Comprehensive Economic Cooperation Agreement (MICECA), effective since July 2011, facilitates trade between the two nations, potentially offering preferential treatment for certain goods. However, specific details regarding pharmaceutical products under this agreement should be verified with the latest trade regulations. There are no current anti-dumping duties imposed on pharmaceutical imports from India.

India is a significant supplier of pharmaceutical products to Malaysia, including Arishta formulations. Other major supplying countries include China, Germany, and the United States. India's share in Malaysia's total pharmaceutical imports is approximately 15%, with herbal formulations accounting for a smaller fraction. Indian pharmaceutical products are generally competitively priced compared to those from European manufacturers, offering cost advantages without compromising on quality. This pricing strategy, combined with established trade relations and the presence of Indian pharmaceutical companies in Malaysia, strengthens India's position in the market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. The country's pharmaceutical industry is supported by a robust infrastructure, including over 3,000 drug companies and 10,500 manufacturing units. This extensive network enables the large-scale production of finished dosage forms, such as tablets, capsules, and syrups, containing Arishta.

The cost structure of Indian pharmaceutical manufacturing offers significant advantages. Lower labor costs, efficient production processes, and economies of scale contribute to the competitive pricing of Arishta formulations. Additionally, India boasts a substantial number of WHO-GMP and US FDA-approved facilities, ensuring compliance with international quality standards. For instance, companies like Alembic Pharmaceuticals and Intas Pharmaceuticals have received multiple US FDA approvals for their manufacturing plants, reflecting their adherence to stringent regulatory requirements.

When comparing Arishta formulation exports from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers offer Arishta formulations at a cost approximately 40% lower than their European counterparts, primarily due to lower production and labor costs. Chinese manufacturers may offer competitive pricing; however, concerns regarding quality and regulatory compliance can affect their market acceptance.

• Quality Perception: Indian pharmaceutical companies are known for their adherence to international quality standards, with numerous facilities holding WHO-GMP and US FDA certifications. In contrast, Chinese manufacturers have faced scrutiny over quality issues, leading to a perception of lower reliability. European manufacturers are recognized for high-quality products but at a higher price point.

• Regulatory Acceptance in Malaysia: Malaysia's regulatory authorities, such as the National Pharmaceutical Regulatory Agency (NPRA), have a history of approving Indian pharmaceutical products, indicating a level of trust and acceptance. Chinese products may face more rigorous scrutiny due to past quality concerns, while European products are generally accepted but come with higher costs.

• Supply Reliability Track Record: Indian manufacturers have demonstrated a reliable supply chain with consistent delivery schedules and capacity to meet large orders. Chinese manufacturers have experienced disruptions due to regulatory interventions and quality issues. European manufacturers maintain a strong track record but may have longer lead times and higher costs.

The India-Malaysia supply chain for Arishta formulations is robust, supported by India's substantial manufacturing capacity. Facilities such as those operated by Alembic Pharmaceuticals and Intas Pharmaceuticals have been inspected and approved by international regulatory bodies, including the US FDA and WHO-GMP, ensuring compliance with global standards.

Packaging and cold chain capabilities in India are well-developed, with manufacturers investing in state-of-the-art infrastructure to maintain product integrity during transit. For example, companies like Caplin Point Laboratories have established advanced facilities for sterile injectables, ensuring quality preservation throughout the supply chain.

Recent data indicates no significant supply disruptions in the India-Malaysia pharmaceutical trade, reflecting the reliability of Indian manufacturers. Regulatory compliance is a priority, with companies undergoing regular inspections and obtaining necessary certifications to meet international standards. While some manufacturers are expanding their capacities to meet growing global demand, there are currently no major capacity constraints reported among top Indian formulation manufacturers.

For Malaysian buyers sourcing Arishta formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Arishta formulations.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary among manufacturers. Establish clear agreements on order sizes to align with both parties' production and inventory capabilities.

• Payment Terms: Standard payment terms in India-Malaysia pharmaceutical trade often include a combination of advance payments and letters of credit. Negotiate terms that balance cash flow considerations with trust-building measures.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications, and assessment of quality control systems to ensure compliance with Malaysian regulatory requirements.

• Regulatory Compliance: Stay updated on Malaysia's NPRA guidelines and ensure that selected Indian suppliers have a history of compliance with these regulations to facilitate smooth product registration and market entry.

1. Verify Product Registration with NPRA: Confirm that the Arishta formulations are registered with Malaysia's National Pharmaceutical Regulatory Agency (NPRA) under the Control of Drugs and Cosmetics Regulations 1984. This ensures the product's legality and compliance within Malaysia.

2. Assess GMP Certification Validity: Obtain the supplier's Good Manufacturing Practice (GMP) certificate, ensuring it is current and issued by a recognized authority. This certificate validates the manufacturer's adherence to quality standards.

3. Review Drug Master File (DMF): Request the DMF to evaluate detailed information about the manufacturing process, quality control, and safety of the Arishta formulations.

4. Evaluate Quality Management Systems: Ensure the supplier has a robust quality management system in place, including standard operating procedures, quality control measures, and compliance with international standards.

5. Confirm Regulatory Approvals: Check for approvals from international regulatory bodies such as the World Health Organization (WHO) or the European Medicines Agency (EMA), indicating global compliance.

6. Conduct Supplier Audits: Plan and perform on-site audits to assess the manufacturing facility's compliance with GMP and other relevant standards.

7. Review Stability Data: Examine stability studies conducted under International Council for Harmonisation (ICH) guidelines to ensure the product maintains its quality over its shelf life.

8. Assess Supply Chain Integrity: Evaluate the supplier's supply chain to ensure traceability and the absence of counterfeit or substandard materials.

9. Verify Insurance Coverage: Confirm that the supplier has adequate insurance coverage for product liability and other potential risks.

10. Check Export History: Review the supplier's export history to ASEAN countries to gauge their experience and reliability in the region.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for each batch, confirming the product meets specified standards.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs and regulatory purposes.

3. GMP Certificate: Issued by a recognized authority, this certificate confirms the manufacturing facility complies with GMP standards.

4. Stability Data: Includes results from stability studies conducted under ICH guidelines, demonstrating the product's shelf life and storage conditions.

5. Batch Manufacturing Records: Detailed records of the manufacturing process for each batch, ensuring consistency and traceability.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, quality control, and safety information of the product.

7. Free Sale Certificate from CDSCO: Issued by the Central Drugs Standard Control Organization (CDSCO), indicating the product is approved for sale in India.

8. Insurance Certificates: Proof of product liability insurance and other relevant coverage to mitigate potential risks.

1. Regulatory Non-Compliance: Recent warning letters or sanctions from regulatory bodies such as the U.S. FDA or WHO-GMP suspensions indicate serious compliance issues.

2. Unusually Low Pricing: Prices significantly below market rates may suggest compromised quality or substandard materials.

3. Lack of Stability Data: Inability to provide comprehensive stability studies raises concerns about product shelf life and efficacy.

4. Limited Export Experience: No history of exporting to ASEAN or Southeast Asian markets may indicate unfamiliarity with regional regulatory requirements.

5. Resistance to Audits: Hesitation or refusal to allow facility audits suggests potential compliance or quality issues.

6. Inconsistent Documentation: Discrepancies or incomplete information in provided documents can indicate poor record-keeping or attempts to conceal issues.

1. Pre-Audit Desktop Review: Analyze all provided documentation, including GMP certificates, CoAs, and DMFs, to identify potential areas of concern before the on-site audit.

3. Post-Audit Corrective Actions: Document findings and require the supplier to address any deficiencies within a specified timeframe, providing evidence of corrective actions taken.

4. Annual Re-Qualification Process: Conduct yearly audits to ensure ongoing compliance and address any new issues that may arise.

5. Remote Monitoring Options: Implement regular virtual meetings, document reviews, and third-party inspections to maintain oversight between on-site audits.

6. Cost Estimates and Timeline: Budget for travel, accommodation, and audit fees, with a typical on-site audit process taking 3-5 days, excluding travel time.

By meticulously following these guidelines, Malaysian companies can establish reliable partnerships with Indian Arishta manufacturers, ensuring the consistent supply of high-quality pharmaceutical formulations.